First participant dosed in Ionis’ Phase I-II ASCEND study
The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome.
News
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Prilenia and Ferrer begin Phase III trial of Huntington’s therapy
Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment
Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial
